{
    "organizations": [],
    "uuid": "03796a33153c77ee96242d2d4742bb6da140e3d0",
    "author": "",
    "url": "https://www.reuters.com/article/brief-morphosys-galapagos-initiate-iguan/brief-morphosys-galapagos-initiate-iguana-phase-2-clinical-trial-with-mor106-in-atopic-dermatitis-patients-idUSFWN1S80KX",
    "ord_in_thread": 0,
    "title": "BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1, 2018 / 8:27 PM / Updated 11 minutes ago BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients Reuters Staff 1 Min Read\nMay 1 (Reuters) - Morphosys Ag:\n* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS\n* PLACEBO CONTROLLED, DOUBLE-BLIND STUDY WILL EVALUATE EFFICACY, SAFETY AND PHARMACOKINETICS (PK) OF MOR106 Source text for Eikon: Further company coverage:",
    "published": "2018-05-01T23:27:00.000+03:00",
    "crawled": "2018-05-01T23:42:17.023+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "galapagos",
        "initiate",
        "iguana",
        "phase",
        "clinical",
        "trial",
        "mor106",
        "atopic",
        "dermatitis",
        "patient",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "morphosys",
        "ag",
        "morphosys",
        "galapagos",
        "announce",
        "initiation",
        "iguana",
        "phase",
        "clinical",
        "trial",
        "mor106",
        "atopic",
        "dermatitis",
        "patient",
        "placebo",
        "controlled",
        "study",
        "evaluate",
        "efficacy",
        "safety",
        "pharmacokinetics",
        "pk",
        "mor106",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}